

# Viktor KoÄka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3739102/publications.pdf>

Version: 2024-02-01

57  
papers

2,990  
citations

471509

17  
h-index

182427

51  
g-index

58  
all docs

58  
docs citations

58  
times ranked

3339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1129-1136.	2.6	9
2	Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe. <i>European Heart Journal Supplements</i> , 2022, 24, B3-B9.	0.1	3
3	Predictors allowing early discharge after interventional treatment of acute coronary syndrome patients. <i>European Heart Journal Supplements</i> , 2022, 24, B10-B15.	0.1	1
4	OUP accepted manuscript. <i>European Heart Journal Supplements</i> , 2022, 24, B36-B41.	0.1	2
5	Long-term follow-up in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. <i>European Heart Journal Supplements</i> , 2022, 24, B16-B22.	0.1	5
6	OUP accepted manuscript. <i>European Heart Journal Supplements</i> , 2022, 24, B23-B27.	0.1	1
7	What antithrombotic treatment is required in a patient after TAVI in the year 2021?. <i>Intervencni A Akutni Kardiologie</i> , 2021, 20, 111-115.	0.0	0
8	Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 24.	2.4	11
9	OCT findings of radiotherapy-induced coronary artery disease: A "two-hit combined hypothesis". <i>Journal of Cardiology Cases</i> , 2020, 22, 149-151.	0.5	0
10	Intravascular haemolysis after transcatheter aortic valve implantation with self-expandable prosthesis: incidence, severity, and impact on long-term mortality. <i>European Heart Journal Supplements</i> , 2020, 22, F44-F50.	0.1	3
11	Optimal Fluoroscopic Projections of Coronary Ostia and Bifurcations Defined by Computed Tomographic Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2560-2570.	2.9	28
12	Bioresorbable scaffold implantation in STEMI patients: 5-years imaging subanalysis of PRAGUE-19 study. <i>Journal of Translational Medicine</i> , 2020, 18, 33.	4.4	8
13	Transcatheter aortic valve implantation - what do we know in 2020. <i>Vnitřni Lekarství</i> , 2020, 66, 282-286.	0.2	1
14	Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 577-582.	0.8	7
15	Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective. <i>Heart and Vessels</i> , 2019, 34, 557-563.	1.2	8
16	Optical coherence tomography in STEMI with bioresorbable scaffold: possible cause of coronary flow impairment? A sub-study from the Prague 19 trial. <i>Heart and Vessels</i> , 2018, 33, 1282-1287.	1.2	1
17	Takotsubo Cardiomyopathy: One More Angiographic Evidence of Microvascular Dysfunction. <i>BioMed Research International</i> , 2018, 2018, 1-6.	1.9	11
18	Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement. <i>Journal of Cardiology</i> , 2017, 69, 483-488.	1.9	8
20	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	2.8	47
21	Use of Amplatzer occluders for treatment of aorto-pulmonary fistulas – case and review of the literature. <i>Expert Review of Medical Devices</i> , 2017, 14, 845-847.	2.8	2
22	Bioresorbable vascular scaffold - good idea worth further effort. <i>Intervencni A Akutni Kardiologie</i> , 2017, 16, 106-108.	0.0	0
23	Invasive Hemodynamic Assessment of Cardiac Output State after MitraClip Therapy in Nonanaesthetized Patients with Functional Mitral Regurgitation. <i>BioMed Research International</i> , 2016, 2016, 1-7.	1.9	8
24	TCT-404 ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison. <i>Journal of the American College of Cardiology</i> , 2016, 68, B164.	2.8	0
25	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. <i>International Journal of Cardiology</i> , 2016, 214, 483-484.	1.7	20
26	Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 131-140.	3.0	21
27	Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. <i>Heart and Vessels</i> , 2016, 31, 841-845.	1.2	9
28	Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients – Results from PRAGUE-19 study. <i>International Journal of Cardiology</i> , 2016, 209, 20-21.	1.7	4
29	Manual aspiration thrombectomy devices use in coronary interventions in 2016. <i>Expert Review of Medical Devices</i> , 2016, 13, 243-251.	2.8	0
30	Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. <i>EuroIntervention</i> , 2016, 12, 23-29.	3.2	18
31	Spatially Organized Structure of Coronary Thrombus in Acute Myocardial Infarction. <i>Blood</i> , 2016, 128, 716-716.	1.4	0
32	Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (Thrombectomy versus PCI ALone) trial. <i>European Heart Journal</i> , 2015, 36, 1892-1900.	2.2	60
33	One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002933.	3.9	10
34	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 189-197.	2.9	145
35	Transcatheter aortic valve implantation: long-term clinical outcome and valve durability. <i>Expert Review of Medical Devices</i> , 2015, 12, 529-535.	2.8	9
36	Potential role of invariant natural killer T cells in outcomes of acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 187, 663-665.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. <i>New England Journal of Medicine</i> , 2015, 372, 1389-1398.	27.0	536
38	Absorb bioresorbable stents for the treatment of coronary artery disease. <i>Expert Review of Medical Devices</i> , 2015, 12, 545-557.	2.8	6
39	Feasibility and repeatability of optical coherence tomography measurements of pre-stent thrombus burden in patients with STEMI treated with primary PCI. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 96-107.	1.2	31
40	Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. <i>European Heart Journal</i> , 2014, 35, 787-794.	2.2	120
41	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 1-6.	2.1	5
42	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	27.0	695
43	ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. <i>European Heart Journal</i> , 2013, 34, 2073-2073.	2.2	9
44	Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>BioMed Research International</i> , 2013, 2013, 1-3.	1.9	14
45	High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 349-354.	2.1	17
46	Five year two center retrospective analysis of patients with toxic digoxin serum concentration. <i>International Journal of Cardiology</i> , 2011, 146, 447-448.	1.7	4
47	Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: A single-center pilot randomised study. <i>International Journal of Cardiology</i> , 2011, 150, 231-232.	1.7	7
48	Platelet-derived chemokines, PF-4 and RANTES, are significantly increased in hemodynamically significant degenerative aortic stenosis. <i>International Journal of Cardiology</i> , 2011, 152, 273-275.	1.7	2
49	Cardiac resynchronization therapy implantation following transcatheter aortic valve implantation. <i>Europace</i> , 2011, 13, 290-291.	1.7	15
50	The Bioresorbable Stent in Perspective—How Much of an Advance is It?. <i>Interventional Cardiology Review</i> , 2011, 9, 23.	1.6	1
51	Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysis. <i>European Journal of Heart Failure</i> , 2010, 12, 634-636.	7.1	22
52	Heart Failure With Preserved Ejection Fraction in Outpatients With Unexplained Dyspnea. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1701-1710.	2.8	154
53	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	27.0	560
54	Predictors of Improvement of Unrepaired Moderate Ischemic Mitral Regurgitation in Patients Undergoing Elective Isolated Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2009, 120, 1474-1481.	1.6	122

#	ARTICLE	IF	CITATIONS
55	Clpidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. <i>European Heart Journal</i> , 2008, 29, 1495-1503.	2.2	132
56	Ibutilide-Induced Cardioversion of Atrial Fibrillation During Pregnancy. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 545-547.	1.7	49
57	Successful treatment of massive pulmonary embolism with prolonged catheter-directed thrombolysis. <i>Heart and Vessels</i> , 2006, 21, 124-126.	1.2	10